【摘要】观察一例初诊肥胖2型糖尿病患者经长效人胰高糖素样肽-1(GLP-1)类似物——利拉鲁肽单药治疗三个月，除血糖控制平稳，血压、血脂改善，体重下降，同时胰岛功能及胰岛素敏感性改善，无低血糖发生，无明显不良反应。该治疗方案为初发T2DM患者提供了一个新的靶点，有望成为早期治疗的理想药物。

　　【关键词】 长效人胰高糖素样肽-1类似物 肥胖 初诊 糖尿病，2型 胰岛功能

　　Improvement of pancreatic islet function of one obese patient treated by long-acting human GLP-1 analogue Liraglutide singly JIANG Lin, YANG Tao. Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029

　　Corresponding author: YANG Tao, E-mail: dryangtao@sina.com

　　【Summary】 In this report, one case of obese patient, newly diagnosed T2DM, was treated with long-acting human glucagon like peptide-1 (GLP-1) analogue Liraglutide singly for three months. In addition to his glycemic control, an improvement in his blood pressure and blood lipid and weight loss was achieved after treatment. What is more that his pancreatic islet function and insulin sensitivity were also changed better. There was no hypoglycemia and other obvious adverse reactions observed during the treatment. This therapeutic scheme provided a new target for newly diagnosed T2DM patients. Liraglutide is expected to become an ideal drug for early treatment of such patients.

　　【Key words】 Long-acting human glucagon like peptide-1 (GLP-1) analogue; Obese; Liraglutide; Newly diagnosed T2DM patient; Islet